STATEMENT OF NEED

Prostate cancer is the most common cancer in men and the second most common cause of cancer death in men, accounting for 30% of new cancer diagnoses and 11% of cancer deaths in males. When diagnosed in early stages, 5- and 10-year survival rates are high; however, 5-year survival remains under 50% if disease is first detected when metastatic (Siegel et al, 2024). The last 15 years have seen significant advances in systemic therapeutic options for prostate cancer, rendering molecular testing necessary for selecting optimal therapy. Improving outcomes for patients relies on collaboration amongst the care team; pathologists have the crucial expertise for interpreting test results, while nurses play a critical role in connecting patients with support and preventing and managing adverse events. In this Virtual Tumor Board Challenge, Stephen Freedland, MD, Professor of Urology at Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center; Andrés Matoso, MD, Professor of Pathology, Urology, and Oncology at Johns Hopkins School of Medicine; and Jennifer Sutton, RN, BS, CCRC, Director of Nursing and Study Operations at START Carolinas, the START Center for Cancer Research, will navigate treatment selection and sequencing in metastatic prostate cancer through patient case studies. 

TARGET AUDIENCE

Medical and radiation oncologists, urologists, pathologists, oncology nurses, advanced practice providers, and other healthcare professionals involved in the treatment of patients with prostate cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

• Apply molecular testing and imaging results to optimize treatment selection for patients with metastatic prostate cancer
• Implement evidence-based sequencing strategies for novel agents and combination regimens in metastatic prostate cancer
• Integrate shared decision-making approaches into care plans, considering patient preferences and potential treatment toxicities

REGISTRATION

There is no fee to participate in or claim CME/NCPD/AAPA credit for this activity.

PROVIDED BY

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 11/24/26. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development

A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.8 ANCC contact hours of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour. 

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1.0 ILNA point toward:

• Care Continuum (OCN®, CBCN®, CPHON®, AOCNP®)
• Oncology Nursing Practice (OCN®)
• Roles of the APRN (AOCNP®)
• Treatment (OCN®, CBCN®, AOCNP®, CPHON®)

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Stephen Freedland, MD, discloses that he has served on an advisory board or panel for Astellas, AstraZeneca, Bayer, Janssen, Merck, Novartis, Pfizer, Sanofi, Sumitomo, and Tolmar; that he has served on a speaker’s bureau for Astellas and Pfizer; and that he has served as a consultant for Astellas, AstraZeneca, Bayer, Janssen, Merck, Novartis, Pfizer, Sanofi, Sumitomo, and Tolmar.

Andrés Matoso, MD, discloses that he has served on an advisory board or panel for Lilly and that he has served as a consultant for Compugen and Diagnexia.

Jennifer Sutton, RN, BS, CCRC, discloses that she has served on an advisory board or panel for Bayer and Merck; that she has served on a speaker’s bureau for Bayer; and that she has served as a consultant for Janssen.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must watch the video and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME/NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME/NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

Supported by educational funding provided by AstraZeneca and Merck Sharpe & Dohme, LLC

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.